Phase 1B Study of Mehd7945A (Mehd) Plus Cisplatin/Fluorouracil (Cis/5Fu) or Carboplatin/Paclitaxel (Carbo/Pac) for 1St-Line Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck (Rmscchn)
Paul M. Clément(Universitair Ziekenhuis Leuven), Antonio Jimeno(University of Colorado Cancer Center), Tanguy Y. Seiwert(Georgetown University), Andrea Pirzkall(Unknown), Lori J. Wirth(Massachusetts General Hospital), Pol Specenier(Antwerp University Hospital), Amy V. Kapp(Humboldt-Universität zu Berlin), Jean‐Pascal Machiels(Cliniques Universitaires Saint-Luc), Stephanie Royer‐Joo(Princess Margaret Cancer Centre), X. Wang, Elicia Penuel, B. McCall, F. Mardjuadi(Cliniques Universitaires Saint-Luc)
Cited by 3
Related Papers
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994